Literature DB >> 32656696

Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.

Maliheh Ghadir1, Mohammad E Khamseh2, Mahshid Panahi-Shamsabad3, Mohammad Ghorbani4, Hamideh Akbari1,5, Ali Zare Mehrjardi3, Maryam Honardoost1, Bahram Jafar-Mohammadi6.   

Abstract

PURPOSE: Non-functioning pituitary adenoma (NFPA) is the most prevalent pituitary macroadenoma. No prognostic marker has been found to explain the behavior of these tumors. We aimed to explore cell proliferation, apoptosis, proangiogenic markers, and microvascular density (MVD) in noninvasive and invasive NFPAs.
METHODS: Adenoma invasiveness was defined according to Knosp and Hardy classifications based on preoperative magnetic resonance imaging scans. Cell proliferation was examined using Ki67 and P53. Tissue expression of Bcl-2 was used to assess the antiapoptosis pathway. CD34 and CD105 were measured to evaluate MVD, while VEGF expression was assessed as an indicator of pro-angiogenesis. Moreover, VEGF, bFGF, endocan, and endostatin were measured on preoperative serum samples.
RESULTS: Tissue and serum markers were examined in 18 patients with invasive and 21 patients with noninvasive NFPAs. Ki67 less than 3% was reported in 10 invasive and 14 noninvasive NFPAs (P = 0.752). P53 staining was negative in all subjects. In addition, Bcl-2 staining was negative in 15 and 20 subjects, respectively (P = 0.718). VEGF-A expression 2+ or 3+ was reported in 9 invasive and 11 noninvasive macroadenomas (P = 0.83). Moreover, CD34 and CD105 positivity were comparable between the two groups. Furthermore, the comparison of serum markers showed no significant differences.
CONCLUSION: Cell proliferation, apoptosis, and angiogenesis play a limited role in NFPA behavior.

Entities:  

Keywords:  Angiogenesis; Apoptosis; Nonfunctional pituitary adenoma; Proliferation; Tumor invasiveness

Mesh:

Year:  2020        PMID: 32656696     DOI: 10.1007/s12020-020-02366-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  45 in total

1.  VEGF and CD31 association in pituitary adenomas.

Authors:  Carolina Cristina; María Inés Perez-Millan; Guillermina Luque; Raúl Ariel Dulce; Gustavo Sevlever; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

Review 2.  Microvascular morphometrics of the hypophysis and pituitary tumors: from bench to operating theatre.

Authors:  Antonio Di Ieva; Andrea Weckman; Joseph Di Michele; Fabio Rotondo; Fabio Grizzi; Kalman Kovacs; Michael D Cusimano
Journal:  Microvasc Res       Date:  2013-05-04       Impact factor: 3.514

Review 3.  Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas.

Authors:  Georgia Ntali; John A Wass
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 4.  Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects.

Authors:  Moises Mercado; Virgilio Melgar; Latife Salame; Dalia Cuenca
Journal:  Endocrinol Diabetes Nutr       Date:  2017-07-04

5.  Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.

Authors:  María Niveiro; F Ignacio Aranda; Gloria Peiró; Cristina Alenda; Antonio Picó
Journal:  Hum Pathol       Date:  2005-10       Impact factor: 3.466

6.  Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma.

Authors:  Aurélie Cornelius; Christine Cortet-Rudelli; Richard Assaker; Olivier Kerdraon; Marie-Hélène Gevaert; Vincent Prévot; Philippe Lassalle; Jacqueline Trouillas; Maryse Delehedde; Claude-Alain Maurage
Journal:  Brain Pathol       Date:  2012-03-16       Impact factor: 6.508

7.  Predicting recurrence of nonfunctioning pituitary adenomas.

Authors:  Tae-Woong Noh; Hyeong Jae Jeong; Mi-Kyung Lee; Tai Seung Kim; Sun Ho Kim; Eun Jig Lee
Journal:  J Clin Endocrinol Metab       Date:  2009-10-09       Impact factor: 5.958

Review 8.  Diagnosis and Treatment of Pituitary Adenomas: A Review.

Authors:  Mark E Molitch
Journal:  JAMA       Date:  2017-02-07       Impact factor: 56.272

9.  Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour.

Authors:  H E Turner; Z Nagy; K C Gatter; M M Esiri; J A Wass; A L Harris
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

10.  A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion.

Authors:  Yanming Miao; Miao Zong; Tao Jiang; Xuesen Yuan; Shusen Guan; Yisong Wang; Dabiao Zhou
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

View more
  5 in total

1.  A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.

Authors:  Nazanin Hosseinkhan; Maryam Honardoost; Zahra Emami; Sara Cheraghi; Nahid Hashemi-Madani; Mohammad E Khamseh
Journal:  Endocrine       Date:  2022-06-16       Impact factor: 3.925

2.  Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas.

Authors:  Jianhua Cheng; Ruya Sun; Ding Nie; Bin Li; Song Bai Gui; Chu Zhong Li; Ya Zhuo Zhang; Peng Zhao
Journal:  Front Surg       Date:  2022-06-21

3.  Taraxasterol prompted the anti-tumor effect in mice burden hepatocellular carcinoma by regulating T lymphocytes.

Authors:  Feng Ren; Yu Zhang; Yuanhua Qin; Jingli Shang; Yanling Wang; Pengkun Wei; Jiaming Guo; Huijie Jia; Tiesuo Zhao
Journal:  Cell Death Discov       Date:  2022-05-16

4.  Predicting Subtype of Growth Hormone Pituitary Adenoma based on Magnetic Resonance Imaging Characteristics.

Authors:  Chen-Xi Liu; Sheng-Zhong Wang; Li-Jun Heng; Yu Han; Yu-Hui Ma; Lin-Feng Yan; Ying Yu; Wen Wang; Yu-Chuan Hu; Guang-Bin Cui
Journal:  J Comput Assist Tomogr       Date:  2022 Jan-Feb 01       Impact factor: 1.826

Review 5.  Differences of Angiogenesis Factors in Tumor and Diabetes Mellitus.

Authors:  Shidong Tan; Guangyao Zang; Ying Wang; Zhen Sun; Yalan Li; Cheng Lu; Zhongqun Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-24       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.